Cellemedy

Cellemedy is a South Korean biotechnology company founded in 2016 by CEO Hachul Kim. The company is headquartered in Seongnam and focuses on developing next-generation cancer immunotherapies designed to replace conventional antibody treatments. Hachul Kim holds a Ph.D. in Chemical Engineering from Virginia Tech and has prior management experience at Exxon Mobil, Fujitsu, and Samsung SDI.

The company's core technology is the T-sphaera™ platform, which utilizes ferritin to create multi-target immune checkpoint inhibitors and drug conjugates. This platform aims to develop therapies that are effective regardless of the patient's PD-L1 expression levels, a limitation in some current treatments. The protein-based nature of the T-sphaera™ platform is designed to reduce immune-related side effects and offer a better safety profile. Cellemedy's pipeline includes several candidates, such as TSIT-01 and TSDC-01, targeting various cancers. The company's approach allows for the simultaneous engagement of multiple immune targets, which may lead to more durable anti-tumor responses.

Cellemedy operates as a private entity and has secured approximately $12.5M in funding from investors including Stonebridge Ventures, CKD Venture Capital, and the Tech Incubator Program for Startup (TIPS). The company's business model is centered on the research and development of its proprietary biopharmaceuticals. It has established partnerships for co-development, such as a memorandum of understanding (MOU) with JD Bioscience for Protein-Drug Conjugate (PDC) development. The company is actively involved in the research and development of tetraspecific antibodies, positioning itself among key players in this emerging field.

Keywords: cancer immunotherapy, biotechnology, multi-target therapeutics, T-sphaera platform, immune checkpoint inhibitors, protein drug conjugate, oncology, biopharmaceuticals, ferritin platform, antibody treatments, cancer therapy, drug development, preclinical trials, tetraspecific antibodies, TSIT-01, next-generation immunotherapy, Hachul Kim, Seongnam, South Korea